NeuroMetrix to Target Chronic Knee Pain with Quell 2.0 Wearable Pain Relief Device
NeuroMetrix, Inc. announced that it has launched a marketing initiative focusing on chronic knee pain. This effort includes direct-to-consumer digital marketing as well as informing physicians and other health care providers about the use of Quell for their patients with knee pain.
About one-quarter of U.S. adults suffer from frequent knee pain, which limits function, decreases mobility, impacts sleep and reduces quality of life. Chronic knee pain is typically treated with oral non-steroidal anti-inflammatory drugs and occasionally prescription opioids. These medications have side effects and, in the case of opioids, may lead to addiction. Surgery is an effective option for some individuals with chronic knee pain.
Quell is the wearable Transcutaneous electrical nerve stimulation (TENS) device. NeuroMetrix states that Quell is suited to chronic knee pain because it is worn just below the knee, is not much larger than a credit card, and is comfortable enough to use 24/7.
Quell is the TENS device with specific FDA 510(k) clearance for use while sleeping. According to the Company’s Quell Health Cloud, regular Quell users with knee pain wear their device for 10 hours a day and 40% use it while sleeping.
The recent version, Quell 2.0, was launched in late 2018 and represents the advanced TENS technology on the market.
Neha writes articles on sectors including medicine, food, materials, and science & technology. A qualified statistician, she has the ability to observe and analyze the trends in global markets and write compelling articles that help CXOs in decision making. She is a bookworm and loves to read fiction, lifestyle, science and technology. Neha comes with 6 years of experience in content writing and editing that involves blog writing, preparation of study materials and OERs.